financetom
Business
financetom
/
Business
/
Arista Networks forecasts second-quarter revenue above estimates on steady demand for networking gears
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Arista Networks forecasts second-quarter revenue above estimates on steady demand for networking gears
May 26, 2025 2:24 AM

May 6 (Reuters) - Arista Networks ( ANET ) forecast

second-quarter revenue above Wall Street estimates following

upbeat first-quarter results on Tuesday, betting on growing

demand for its networking equipments amid the artificial

intelligence boom.

However, shares of the Santa Clara, California-based company

fell about 7% in extended trading, amid investor concerns over

broader market conditions and renewed tariff fears.

The company, which has a market value of $114 billion, has

seen its stock decline about 18% so far this year, pressured by

ongoing tariff-related worries.

Arista Networks ( ANET ) projects second-quarter revenue of about

$2.1 billion, compared with analysts' estimates of $2.02

billion, according to data compiled by LSEG.

Demand for Arista's products, such as ethernet switches and

routers used in data centers, has surged as companies increase

their investments in artificial intelligence infrastructure.

Moreover, the ongoing tariff war could help domestic

companies such as Arista secure additional contracts with

hyperscale clients, potentially boosting their market share and

revenue growth significantly.

"We surpassed $2 billion in revenue for the first time in Q1

2025 despite the unknowns around tariffs," said Chief Executive

Officer Jayshree Ullal.

The company's customers include some of the largest cloud

service providers, such as Microsoft ( MSFT ) and Meta Platforms ( META )

, which accounted for about 20% and 15% of its total

revenue, respectively, in 2024.

For the quarter ended March 31, Arista's revenue reached

$2 billion, compared to analysts' estimates of $1.97 billion.

On an adjusted basis, the company earned 65 cents per share

in the first quarter, beating analysts' estimate of 59 cents per

share.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Braze Fiscal Q4 Non-GAAP Loss Narrows, Revenue Rises; Fiscal Q1, 2025 Outlook Set
Braze Fiscal Q4 Non-GAAP Loss Narrows, Revenue Rises; Fiscal Q1, 2025 Outlook Set
Mar 27, 2024
04:37 PM EDT, 03/27/2024 (MT Newswires) -- Braze (BRZE) reported a fiscal Q4 non-GAAP net loss late Wednesday of $0.04 per diluted share, compared with a net loss of $0.14 a year earlier. Analysts polled by Capital IQ expected a loss of $0.05. Revenue for the quarter that ended Jan. 31 was $131 million, up from $98.7 million a year...
--Sprinklr Guides For Q1 EPS of $0.07 on Revenue of $194-$195 Million, vs CIQ Analyst Consensus of $0.09/Share on Revenue of $193 Million
--Sprinklr Guides For Q1 EPS of $0.07 on Revenue of $194-$195 Million, vs CIQ Analyst Consensus of $0.09/Share on Revenue of $193 Million
Mar 27, 2024
04:14 PM EDT, 03/27/2024 (MT Newswires) -- Price: 13.03, Change: +0.02, Percent Change: +0.19 ...
Johnson & Johnson Strong Strategic Fit For Shockwave Medical, But Medtronic, Boston Scientific Could Be Other Bidder, Says Analyst
Johnson & Johnson Strong Strategic Fit For Shockwave Medical, But Medtronic, Boston Scientific Could Be Other Bidder, Says Analyst
Mar 27, 2024
Tuesday, Shockwave Medical Inc ( SWAV ) shares traded higher following a Wall Street Journal report suggesting Johnson & Johnson ( JNJ ) is reportedly in talks to acquire the company. Shockwave Medical ( SWAV ) is a cardiovascular medical device. In 2022, Johnson & Johnson ( JNJ ) acquired heart failure device-focused Abiomed Inc. for an upfront payment of $380.00 per share in cash, corresponding to...
The Oncology Institute Q4 Loss Widens, Revenue Increases
The Oncology Institute Q4 Loss Widens, Revenue Increases
Mar 27, 2024
04:46 PM EDT, 03/27/2024 (MT Newswires) -- The Oncology Institute ( TOI ) reported a Q4 loss late Wednesday of $0.21 per diluted share, compared with a loss of $0.16 a year earlier. GAAP EPS was not available on Capital IQ for comparison. Operating revenue for the quarter that ended Dec. 31 was $85.8 million, up from $71.4 million a...
Copyright 2023-2026 - www.financetom.com All Rights Reserved